TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27568199

Group type: EXPERIMENTAL
Intervention: Ketogenic meal (Ketonformula®) containing 20 g of MCTs
Number of subjects: 19

Group type: COMPARATOR
Intervention: Isocaloric placebo meal without MCTs
Number of subjects: 19
Study: 25294887

Group type: EXPERIMENTAL
Intervention: Doxorubicin-based chemotherapy (CT)
Number of subjects: 819

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 819
Study: 22574584

Group type: EXPERIMENTAL
Intervention: Puerarin (0.5 g in 250 mL glucose injection, intravenously once daily for 14 days starting from the 3rd day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (routine treatment only)
Number of subjects: 54
Study: 20392594

Group type: EXPERIMENTAL
Intervention: High-frequency right prefrontal rTMS (10Hz, 110% of motor threshold, 4s per train, 20 trains per session)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-frequency right prefrontal rTMS
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 42
Study: 17003527

Group type: EXPERIMENTAL
Intervention: Itraconazole comedication
Number of subjects: 20

Group type: COMPARATOR
Intervention: No itraconazole comedication
Number of subjects: 20
Study: 15748091

Group type: EXPERIMENTAL
Intervention: Sivelestat (0.20 mg/kg/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (0.004 mg/kg/h, effectively a placebo)
Number of subjects: 0
Study: 12141718

Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg/pseudoephedrine 120 mg
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 9928802

Group type: EXPERIMENTAL
Intervention: Different brands of tape for patch tests with 2 mg/cm2 sodium dodecyl sulfate (SLS) applied for 24 hours.
Number of subjects: 10
Study: 7762544

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg, s.c.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone administration in healthy subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone administration in opiate-dependent patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Opiate withdrawal in patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy subjects receiving naloxone
Number of subjects: 20
Study: 2306419

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no cimetidine)
Number of subjects: 0
Study: 374161

Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31111923

Group type: EXPERIMENTAL
Intervention: Dryland rearing on netting floors (DRNF)
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2280
Study: 28089469

Group type: EXPERIMENTAL
Intervention: Barbed sutures (Stratafix, Ethicon Inc)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Traditional sutures (Vicryl, Ethicon Inc)
Number of subjects: 109
Study: 25503549

Group type: EXPERIMENTAL
Intervention: Expiratory training (n=27)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Inspiratory training (n=26)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham training (n=25)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 82
Study: 21867595

Group type: EXPERIMENTAL
Intervention: Artificial oocyte activation (AOA)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Controlled group
Number of subjects: 386
Study: 20559144

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 8
Study: 19752319

Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg BID
Number of subjects: 4628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4628
Study: 17087362

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/day)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Patients with HCV infection
Number of subjects: 165

Group type: COMPARATOR
Intervention: Patients without HCV infection
Number of subjects: 165

Group type: COMPARATOR
Intervention: C. pneumoniae infection and anti‐HCV positivity
Number of subjects: 165
Study: 15311722

Group type: EXPERIMENTAL
Intervention: Zinc sulphate capsules (50 mg zinc)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11399959

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9118759

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (250 mg t.i.d.)
Number of subjects: 12
Study: 8101050

Group type: EXPERIMENTAL
Intervention: HSV + gastrojejunostomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: HSV + Jaboulay gastroduodenostomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: SV + antrectomy
Number of subjects: 90
Study: 2880872

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31666093

Group type: EXPERIMENTAL
Intervention: Study personnel strategies for patient recruitment
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Barriers to recruitment
Number of subjects: 148
Study: 29931604

Group type: COMPARATOR
Intervention: 0.5% body weight (BW) supplementation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.5% body weight (BW) supplementation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both supplementation levels
Number of subjects: 12
Study: 27146213

Group type: EXPERIMENTAL
Intervention: Brivaracetam 150-200 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coadministration with carbamazepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coadministration with phenytoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coadministration with phenobarbital
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coadministration with levetiracetam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline seizure frequency
Number of subjects: 0
Study: 25229983

Group type: EXPERIMENTAL
Intervention: Clarithromycin-based triple therapy (omeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Empirical triple therapy (omeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days)
Number of subjects: 111
Study: 22579427

Group type: EXPERIMENTAL
Intervention: Traditional Thai massage (TTM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 40
Study: 20459600

Group type: EXPERIMENTAL
Intervention: Soap + low pressure
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: Soap + gravity flow pressure
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: Soap + high pressure
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: Saline + low pressure
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: Saline + gravity flow pressure
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: Saline + high pressure
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 2280
Study: 18753638

Group type: EXPERIMENTAL
Intervention: Aspirin plus extended-release dipyridamole (ASA-ERDP) 25 mg + 200 mg twice daily
Number of subjects: 20332

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily
Number of subjects: 20332

Group type: EXPERIMENTAL
Intervention: Aspirin plus extended-release dipyridamole (ASA-ERDP)
Number of subjects: 20332

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 20332
Study: 16113753

Group type: EXPERIMENTAL
Intervention: Chromogenic assay for functional determination of TFPI
Number of subjects: 7000
Study: 12418644

Group type: EXPERIMENTAL
Intervention: Antibiotic with protected lactobacilli
Number of subjects: 740

Group type: COMPARATOR
Intervention: Plain antibiotic (ampicillin 250 mg and cloxacillin 250 mg)
Number of subjects: 740
Study: 10343624

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (1500 micrograms beclomethasone daily, 1600 micrograms budesonide daily, 800 micrograms beclomethasone daily)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 7555480

Group type: EXPERIMENTAL
Intervention: Intensive therapy (multiple daily injections (MDI) of insulin or continuous subcutaneous insulin infusion (CSII))
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1441
Study: 2037265

Group type: EXPERIMENTAL
Intervention: Cabergoline 1 mg p.o. (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bromocriptine 5 mg/day p.o. for 14 days (n = 18)
Number of subjects: 36
Study: 30265024

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (24 hours)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (participants who slept at home)
Number of subjects: 234
Study: 28716215

Group type: EXPERIMENTAL
Intervention: Bio‐Gide collagen membrane (experimental group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No collagen membrane (control group)
Number of subjects: 43
Study: 26536327

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control
Number of subjects: 187
Study: 24117655

Group type: EXPERIMENTAL
Intervention: Motor performance (Finger Tapping Test)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Cognitive performance (Trail Making Test)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Breath alcohol concentration (BrAC)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Alcohol-related stimulant effects
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Alcohol-related sedative effects
Number of subjects: 280
Study: 21727728

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 160
Study: 19723863

Group type: EXPERIMENTAL
Intervention: 0.12% solution chlorhexidine oral swab twice daily
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Toothbrushing thrice daily
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Both toothbrushing and chlorhexidine
Number of subjects: 547

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 547
Study: 17727664

Group type: EXPERIMENTAL
Intervention: 20% mannitol (1.5 g/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 15128353

Group type: EXPERIMENTAL
Intervention: PEG-IFN alpha2a (180 microg/wk) and ribavirin (1-1.2 g/d) with addition of 200 mg amantadine
Number of subjects: 6

Group type: COMPARATOR
Intervention: PEG-IFN alpha2a (180 microg/wk) and ribavirin (1-1.2 g/d) with placebo
Number of subjects: 6
Study: 11490709

Group type: EXPERIMENTAL
Intervention: Categel (sterile gel of methylcellulose with 2% lidocaine and 0.05% chlorhexidine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Categel S (contains the same components but without lidocaine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Categel
Number of subjects: 0
Study: 11367659

Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (TCM‐WM)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 83
Study: 7802064

Group type: EXPERIMENTAL
Intervention: Middle-cerebral-to-umbilical-artery ratio cutoff value of 1.0
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (healthy women with uncomplicated singleton pregnancies)
Number of subjects: 135
Study: 3042644

Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg orally daily for three months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31594037

Group type: EXPERIMENTAL
Intervention: Upadacitinib (3, 6, 12, 24 mg b.i.d. or 24 mg q.d.)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 29605825

Group type: EXPERIMENTAL
Intervention: Lemonade (2 mEq/kg/day citrate) for 5 days
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Potassium citrate (2 mEq/kg/day) for 5 days
Number of subjects: 126
Study: 27537364

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Multisensory stimulation
Number of subjects: 80
Study: 23731019

Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg for 4 weeks, then 160 mg for 20 weeks)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 22725606

Group type: EXPERIMENTAL
Intervention: Thickened preterm formula (TPF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Preterm formula (PF)
Number of subjects: 28
Study: 20357044

Group type: EXPERIMENTAL
Intervention: 250 mg trans-resveratrol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 500 mg trans-resveratrol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 18372278

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg) plus Spironolactone (25 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no medications)
Number of subjects: 17
Study: 15992642

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance imaging (CMR)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (healthy volunteers and athletes)
Number of subjects: 235
Study: 12881382

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) in postmenopausal patients
Number of subjects: 167

Group type: COMPARATOR
Intervention: Observation in premenopausal women
Number of subjects: 167

Group type: COMPARATOR
Intervention: Observation in premenopausal patients
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) in premenopausal patients
Number of subjects: 167
Study: 10579148

Group type: EXPERIMENTAL
Intervention: rBPI21 30-minute infusion at doses of 0.25 to 4 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rBPI21 24- to 48-hour infusion at doses of 2 to 8 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model for clearance of rBPI21
Number of subjects: 0
Study: 8743521

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 to 40 mg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Enalapril (5 to 20 mg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 13
Study: 1959070

Group type: EXPERIMENTAL
Intervention: CPEP services (n = 97)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Traditional community services (n = 94)
Number of subjects: 191
Study: 6803288

Group type: EXPERIMENTAL
Intervention: + tranylcypromine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: - tranylcypromine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29578820

Group type: EXPERIMENTAL
Intervention: MSHC with ACP to the moving arm
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MSHC without ACP to BSaMA
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MSHC with ACP to the stationary arm
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MSHC with ACP to BSaMA
Number of subjects: 39
Study: 30283022

Group type: EXPERIMENTAL
Intervention: Standardized isotonic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nocebo
Number of subjects: 0
Study: 27275651

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose followed by 90 mg maintenance dose twice daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Prasugrel (60 mg loading dose followed by 10 mg maintenance dose once daily)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ticagrelor vs. Prasugrel
Number of subjects: 70
Study: 25102717

Group type: EXPERIMENTAL
Intervention: Computerized injection technique (CIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional infiltration technique with traditional syringe
Number of subjects: 28
Study: 22340861

Group type: EXPERIMENTAL
Intervention: Palmar plate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dorsal Pi-plate
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 19816918

Group type: EXPERIMENTAL
Intervention: Physiotherapy-supervised pelvic floor muscle training program (1 pre-operative and 7 post-operative sessions over 12 months)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care (as provided by the surgeon and hospital staff)
Number of subjects: 51
Study: 17262041

Group type: EXPERIMENTAL
Intervention: Percutaneous central venous line (PCVL)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Peripheral intravenous catheter (PIV)
Number of subjects: 96
Study: 15226470

Group type: EXPERIMENTAL
Intervention: 400 micro g DFE/d
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 800 micro g DFE/d
Number of subjects: 42

Group type: COMPARATOR
Intervention: 135 micro g DFE/d (low-folate diet)
Number of subjects: 42
Study: 12203757

Group type: EXPERIMENTAL
Intervention: Ganciclovir prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative therapies
Number of subjects: 0
Study: 9798418

Group type: EXPERIMENTAL
Intervention: Home-based intervention including nurse visits providing parenting information
Number of subjects: 20
Study: 7708189

Group type: EXPERIMENTAL
Intervention: Monomeric (iohexol 300 mg I/ml)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Dimeric (iodixanol 270 mg I/ml)
Number of subjects: 76
Study: 2494947

Group type: EXPERIMENTAL
Intervention: ACF alone (Adriamycin, Cyclophosphamide, Ftorafur)
Number of subjects: 47

Group type: COMPARATOR
Intervention: ACF/MVMF (Mitomycin C, Vincristine, Methotrexate, Ftorafur)
Number of subjects: 47
Study: 326337

Group type: EXPERIMENTAL
Intervention: Quinine followed by pyrimethamine-sulfadoxine (Fansidar)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Quinine followed by mefloquine
Number of subjects: 74
Study: 30616482

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no rTMS)
Number of subjects: 58
Study: 27363313

Group type: EXPERIMENTAL
Intervention: l-Tetrahydropalmatine (30 mg twice a day orally)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26653717

Group type: EXPERIMENTAL
Intervention: SenSura Mio Convex Soft
Number of subjects: 38

Group type: COMPARATOR
Intervention: Flat stoma appliance
Number of subjects: 38
Study: 23392129

Group type: EXPERIMENTAL
Intervention: 0.5 mg fluoride milk
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.9 mg fluoride milk
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-fluoride milk (control group)
Number of subjects: 45
Study: 21704236

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 16279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16279
Study: 18418361

Group type: EXPERIMENTAL
Intervention: Memantine (40 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mecamylamine (10 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16966223

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 14723628

Group type: EXPERIMENTAL
Intervention: 9.0 MIU IFNA
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 11168867

Group type: EXPERIMENTAL
Intervention: Single-daily ceftriaxone plus amikacin
Number of subjects: 128

Group type: COMPARATOR
Intervention: Thrice-daily ceftazidime plus amikacin
Number of subjects: 128
Study: 9314382

Group type: EXPERIMENTAL
Intervention: Experimental group (visualization of the tract before THBDC placement)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (blind needle passage without contrast material opacification)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Experimental technique applied to additional 35 patients
Number of subjects: 55
Study: 8222499

Group type: EXPERIMENTAL
Intervention: 300 mg Ro 42-5892
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 600 mg Ro 42-5892
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 300 mg Ro 42-5892 (IV)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 600 mg Ro 42-5892 (IV)
Number of subjects: 49
Study: 2880447

Group type: EXPERIMENTAL
Intervention: Oral temazepam 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29729676

Group type: EXPERIMENTAL
Intervention: Traditional ABM program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive ABM program
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABM (both traditional and adaptive)
Number of subjects: 0
Study: 29521247

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice a day for 12 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 27498244

Group type: EXPERIMENTAL
Intervention: Behavior change intervention involving Madrassa teachers trained in interactive and participatory teaching methods
Number of subjects: 5926

Group type: EXPERIMENTAL
Intervention: Behavior change intervention involving Madrassa teachers
Number of subjects: 5926
Study: 24500028

Group type: EXPERIMENTAL
Intervention: Healthy living intervention
Number of subjects: 105

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 105
Study: 22301208

Group type: EXPERIMENTAL
Intervention: Covered group (Group C) - actively warmed using cotton blankets and a warm forced-air blanket set at 43°C
Number of subjects: 50

Group type: COMPARATOR
Intervention: Uncovered group (Group U) - remained uncovered during the induction of general anesthesia
Number of subjects: 50